(redirected from Cushing's disease)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Cushing's disease: Cushing's syndrome, cortisol, Addison's disease
References in periodicals archive ?
There are multiple tests that can increase the suspicion of Cushing's disease, and these are generally used in tandem to make a diagnosis.
Fujisawa et al., "Systemic lupus erythematosus after pituitary adenomectomy in a patient with Cushing's disease," Clinical Endocrinology, vol.
Petersenn, "Medical management of Cushing's disease: What is the future?" The Pituitary Society, vol.
Flitsch, "Hippocampal and cerebellar atrophy in patients with Cushing's disease," Neurosurgical Focus, vol.
* The report reviews key players involved in the therapeutics development for Pituitary ACTH Hypersecretion (Cushing's Disease) and enlists all their major and minor projects
Biermasz et al., "Subtle cognitive impairments in patients with long-term cure of Cushing's disease," The Journal of Clinical Endocrinology & Metabolism, vol.
They are associated with elevated circulating ACTH and cortisol levels leading to Cushing's disease with features of hypercortisolism.
Other approvals include new drugs to treat Gaucher disease, short bowel syndrome, cystic fibrosis, multiple sclerosis, Cushing's disease, epilepsy, several forms of leukemia, kidney cancer, thyroid cancer, basal cell carcinoma, and AIDS.
They include treatments such as a Kalydeco from Vertex Pharmaceuticals Inc for a rare form of the lung disorder cystic fibrosis and Signifor from Novartis AG for Cushing's disease, caused by over-production of the hormone cortisol.
Pasireotide, a somatostatin analogue, has been approved by the Food and Drug Administration as a treatment for Cushing's disease in adults "for whom pituitary surgery is not an option or has not been curative."
Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.